Clinical trial
A Japanese Phase I Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00923182 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Japanese Phase I Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2010
- Completion date
- August 31, 2011
- Enrollment
- 6 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.